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Abstract: A healthy intestinal barrier prevents uptake of allergens and toxins, whereas intestinal
permeability increases following chemotherapy and in many gastrointestinal and systemic diseases and
disorders. Currently, there are no approved drugs that target and repair the intestinal epithelial barrier
while there is a medical need for such treatment in gastrointestinal and related conditions. The objective
of this single-pass intestinal perfusion study in rats was to investigate the preventive cytoprotective
effect of three mucosal protective drugs—melatonin, misoprostol, and teduglutide—with different
mechanisms of action on an acute jejunal injury induced by exposing the intestine for 15 min
to the anionic surfactant, sodium dodecyl sulfate (SDS). The effect was evaluated by monitoring
intestinal clearance of 51Cr-labeled ethylenediaminetetraacetate and intestinal histology before, during,
and after luminal exposure to SDS. Our results showed that separate pharmacological pretreatments
with luminal misoprostol and melatonin reduced acute SDS-induced intestinal injury by 47% and
58%, respectively, while their use in combination abolished this injury. This data supports further
development of drug combinations for oral treatments of conditions and disorders related to a
dysregulated or compromised mucosal epithelial barrier.
Keywords: intestinal barrier dysfunction; single-pass intestinal perfusion; intestinal permeability;
gastrointestinal physiology
1. Introduction
The role of the intestinal mucosa is to form a selective and dynamic barrier between the external
luminal contents and the underlying tissue and systemic circulation [1]. It should restrict passage of
potentially harmful intestinal constituents, such as microbiota, toxins, and allergens, while allowing
carrier-mediated and/or passive transport of water, nutrients, and ions. The mucosal barrier consists of
a single layer of intestinal epithelial cells (IEC) covered with a mucus layer and the underlying immune
system. The IECs are sealed together at the apical surface by tight junction proteins, which form
the primary physical barrier to transport of small hydrophilic molecules across the epithelium.
Permeation across this barrier is strictly regulated by a range of neuroendocrine processes, hormones,
and luminal stimuli that jointly uphold homeostasis [2,3]. The IECs have a high turnover, being renewed
by cryptal stem cells every five days and shredded at the villus tip. This process takes place without
any loss of intestinal barrier function in a healthy, selective mucosal barrier [4].
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A dysregulated or compromised intestinal barrier permits uptake of potentially toxic xenobiotics
and alters absorptive and secretory physiological functions. This may cause local tissue injury,
including inflammation, as well as extraintestinal manifestations after permeation and spread of
noxious compounds throughout the body. Increased intestinal permeability occurs as a result of
chemotherapy and radiation as well as in a range of gastrointestinal (GI) and systemic diseases and
disorders, such as celiac disease, inflammatory bowel disease, type 1 diabetes, obesity, nonalcoholic
fatty liver disease, alcoholic liver disease, and irritable bowel syndrome [5–8]. However, a true
association between increased intestinal permeability and different disease entities is difficult to define
as it requires a cause and effect analysis through studies of temporal relationships. It is yet unproven
whether reinforcement of the intestinal barrier can prevent or cure GI or systemic clinical manifestations
as there are no approved drugs that target the intestinal epithelial barrier. This opens the possibility
for a new pharmaceutical therapeutic approach.
One potential target for such treatment is the melatonin membrane G protein-coupled MT1 and
MT2 receptors, which are expressed throughout the GI tract of rats and humans [9–11]. Melatonin is
a serotonin derivative synthesized by the enterochromaffin cells in the intestine. It reduces basal
paracellular permeability in the duodenum through an inhibitory nicotinic receptor-mediated neural
pathway in rats [12]. Melatonin has also been shown to reduce ethanol- and radiation-induced increases
of intestinal permeability and injury in rats [13,14].
Mucosal homeostasis and inflammation are also mediated by prostaglandins, which have a host
of complex long- and short-term effects on the intestine, including regulation of bicarbonate secretion,
mucus production, and mucosal blood flow. Misoprostol is a synthetic E-type prostaglandin analogue
with cytoprotective actions in the intestine, partly mediated by inhibited production and release of
cytokines [15]. Misoprostol is used for preventing GI mucosal perturbation and ulcers induced by
nonsteroidal anti-inflammatory drugs [16].
Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, promotes intestinal mucosal growth.
It is indicated for the treatment of short bowel syndrome because it increases intestinal nutrient and
fluid absorption and reduces the need for parenteral support. Teduglutide also protects intestinal stem
cells from radiation damage in mice as well as acid-induced esophageal mucosal damage in rats [17,18].
The main objective of our single-pass intestinal perfusion (SPIP) study in rats was to investigate
the mucosal preventive cytoprotective effect of melatonin, misoprostol, and teduglutide, each with
a different mechanism of action. Intestinal mucosal injury was induced by exposing the intestinal
mucosa to the anionic surfactant, sodium dodecyl sulfate (SDS), for 15 min. This surfactant causes an
acute general mucosal injury manifested by an increase in paracellular and transcellular permeability,
coupled with histological changes and leakage of intracellular components [19,20]. The study drugs
were administered intravenously (IV) and/or luminally before and/or during the SDS exposure.
Mucosal preventive cytoprotective effects of the drugs were evaluated by monitoring intestinal passive
transport of 51Cr-labeled ethylenediaminetetraacetate (51Cr-EDTA)—an inert market for mucosal
barrier integrity—and evaluation of histological changes before, during, and after luminal exposure to
SDS [21].
2. Results
2.1. Blood-to-Lumen 51Cr-EDTA clearance (CLCr-EDTA) over Time Curves, CLAUC, and CLmax
The mean (±SEM) CLCr-EDTA over time (0–120 min) for the nine different experimental designs
(see Table 2 and Figure 5 in the method section) are presented in Figures 1–3. The corresponding
CLAUC and CLmax values calculated from these CLCr-EDTA time curves (45–120 min) are presented in
Table 1.
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Table 1. The area under the blood-to-lumen CLCr-EDTA time curve between 45 and 120 min (CLAUC), and
maximum CLCr-EDTA (CLmax) in the jejunal perfusate of the nine different single-pass intestinal perfusion
experiments (Table 2 and Figure 5). Three experimental drugs—melatonin (MEL), misoprostol (MIS),
and teduglutide (TED)—were luminally (LUM) and/or intravenously (IV) administered, individually or
in combination, to rats in order to evaluate their effects on SDS-induced mucosal damage. Differences in
CLAUC and CLmax compared to the control solution or the SDS solution are presented. The mark *
represents a significantly lower CLAUC/CLmax of the luminal combination of melatonin and misoprostol
compared to melatonin and misoprostol alone. The CLAUC and CLmax values were compared using a
one-way ANOVA with a post-hoc Tukey’s multiple comparison test.
Experiments CLAUC (mL/100 g)
CLmax
(mL/min/100 g)
CLAUC and CLmax Significant
Different from:
Control SDS
Control 10.3 ± 1.6 0.16 ± 0.02 - Yes
Control MEL-LUM 9.6 ± 1.1 0.14 ± 0.02 No Yes
SDS no parecoxib 24.7 ± 3.0 0.47 ± 0.06 Yes No
SDS 22.7 ± 1.8 0.46 ± 0.04 Yes -
SDS TED-IV 25.1 ± 4.6 0.49 ± 0.09 Yes No
SDS MEL-IV 23.7 ± 4.8 0.48 ± 0.10 Yes No
SDS MEL-LUM 16.4 ± 2.1 0.31 ± 0.04 Yes Yes
SDS MIS-LUM 18.0 ± 2.6 0.36 ± 0.05 Yes Yes
SDS MEL-MIS-LUM 10.7 ± 1.6* 0.18 ± 0.03* No Yes
2.2. Effect of Luminal SDS with or without Intravenous Parecoxib or Teduglutide
The CLAUC and CLmax from the CLCr-EDTA time curves (45–120 min) were significantly higher
than for the control solution when SDS was added to the intestinal lumen between 45 and 60 min.
Parecoxib alone had no effect on the SDS-induced increase in CLCr-EDTA (Table 1 and Figure 1a).
A teduglutide bolus followed by infusion (SDS TED-IV) did not affect the SDS-induced increase in
CLAUC and CLmax (Table 1 and Figure 1b).
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Figure 1. The blood-to-lumen 51Cr-EDTA clearance (CLCr-EDTA) between 0 and 120 min for the control 
buffer solution with or without sodium dodecyl sulfate (SDS) at 5 mg/mL added to the luminal 
perfusate between 45 and 60 min. (a) The effect of intravenously pretreating rats with 10 mg/kg 
parecoxib 30 min before the start of the SDS experiment. (b) The effect of intravenously treating rats 
with a 100 μg teduglutide bolus at time 0, followed by a 33 μg/h teduglutide infusion during the 
whole SDS experiment. 
2.3. Effect of Intravenously and Luminally Perfused Melatonin 
A melatonin bolus at 30 min (SDS MEL-IV) did not affect the luminal SDS-induced increase in 
CLAUC and CLmax from the CLCr-EDTA time curves (45–120 min) but resulted in a 15 min delay in the 
SDS-induced increase in CLCr-EDTA (Table 1 and Figure 2a). Luminal addition of melatonin to the 
control (Control MEL-LUM) made no difference in CLAUC and CLmax but significantly decreased the 
SDS-induced CLAUC (51%) and CLmax (50%), (Table 1 and Figure 2b). 
Figure 1. The blood-to-lumen 51Cr-EDTA clearance (CLCr-EDTA) between 0 and 120 min for the control
buffer solution with or without sodium dodecyl sulfate (SDS) at 5 mg/mL added to the luminal p rfusate
betw en 45 and 60 min. (a) The effect of intraveno sly pretreating rats with 10 mg/kg parecoxib
30 min befor the start of the SDS experim nt. (b) The effect f intrav nously t eating rats with a
100 µg teduglut de bolus at time 0, followed by a 33 µg/h teduglutide infusion during the whole
SDS experiment.
2.3. Effect of Intravenously and Luminally Perfused Melatonin
A melatonin bolus at 30 min (SDS MEL-IV) did not affect the luminal SDS-induced increase in
CLAUC and CLmax from the CLCr-EDTA time curves (45–120 min) but resulted in a 15 min delay in the
SDS-induced increase in CLCr-EDTA (Table 1 and Figure 2a). Luminal addition of melatonin to the
Int. J. Mol. Sci. 2020, 21, 6771 4 of 13
control (Control MEL-LUM) made no difference in CLAUC and CLmax but significantly decreased the
SDS-induced CLAUC (51%) and CLmax (50%), (Table 1 and Figure 2b).
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Figure 2. The blood-to-lumen CLCr-EDTA between 0 and 120 min for the control buffer solution with
or without SDS at 5 mg/mL added to the luminal perfusate between 45 and 60 min. (a) The effect of
intravenously treating rats with a 20 mg/kg el tonin bolus 30 min before the start of SDS exposure.
(b) The effect of luminally treating rats with l t i (100 µM) betw en 30 and 120 min in the control
and SDS experi ents. The * represents a significant decrease in CLCr-EDTA exposure of the luminal
melatonin compared to SDS alo e.
2.4. Effect of Luminally Perfused Misoprostol
Luminal misoprostol (SDS MIS-LUM) significantly reduced the SDS-induced increase in CLAUC
(38%) and CL ax (33%) from the CLCr-EDTA time curves (45–120 min), (Table 1 and Figure 3a).
Luminal misoprostol also resulted in a co plete return to baseline CLCr-EDTA at the end of the
recovery period.
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Figure 3. The blood-to-lumen CLCr-EDTA between 0 and 120 min for the control buffer solution with
or without SDS at 5 mg/ L added to th luminal perfusate between 45 and 60 min. (a) The effect
of luminally treating rats with misoprostol (10 µM) between 30 and 120 min in the SDS exp riment.
(b) The effect of luminally treating ats with melatonin (100 µM) and misoprostol (10 µM) between 30
and 120 min in the SDS experiment. The * represents a significant decrease in CLCr-EDTA exposure of
the luminal drug treatments co pared to SDS alone.
2.5. Combination Effect of Luminal Melatonin and Misoprostol
Luminal misopr stol and melatonin in combin tion (SDS MIS-MEL-LUM) completely in ibited
the SDS-induced increase in CLAUC and CLmax from the CLCr-EDTA time curves (45–120 min) (Table 1
and Figure 3b). The combination of melatonin and misoprostol also s gnificantly decreas d CLAUC
and CLmax compared to administration of them separately (Table 1).
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2.6. Histology
The histological investigations displayed no short-term disruption or detachment of epithelial
cells. Neither were there any signs of acute damage or acute inflammation (as determined by the
absence of neutrophils). The only feature that differed between the study groups was a clear edema
in the tip of several villi in the two experimental groups (misoprostol and misoprostol + melatonin)
exposed to misoprostol for 60 min. This was easily seen even with low microscopic magnification
(high magnification is shown in Figure 4a,b). The mucus layer was intact in all animals without any
obvious damage (see Figure 4c).
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 13 
 
absence of neutrophils). The only feature that differed between the study groups was a clear edema 
in the tip of several villi in the two experimental groups (misoprostol and misoprostol + melatonin) 
exposed to misoprostol for 60 min. This was easily seen even with low microscopic magnification 
(high magnification is shown in Figure 4a,b). The mucus layer was intact in all animals without any 
obvious damage (see Figure 4c).  
 
Figure 4. Two pictures (A,B) of hematoxylin and eosin-stained villous tips, and one (C) picture 
showing Alcian blue–PAS (pH 2.5)-stained mucus (original magnification ×400). (A) The villous tip 
contain a moderate, densely packed infiltrate of macrophages, lymphocytes, plasma cells, and 
eosinophils. No neutrophils were present. (B) An edema is shown with an increase of the intercellular 
stroma and a loose presence of inflammatory cells and fibrocytes. Lymphatic and blood vessels are 
dilated. The epithelium is intact. (C) A continuous small layer of magenta-positive mucus at the 
luminal apical face of the enterocytes. The goblet cells display a blue-purple mucus. Apoptotic cells 
and macrophages containing small mucus droplets are seen under the epithelium. Experimental 
groups: (A) melatonin 100 mM, (B) misoprostol 10 mM, and (c) control. 
3. Discussion 
This study investigated the potential of treating an injured intestinal barrier, which is common 
in many GI and systemic diseases [5]. The main objective was to investigate the protective effects and 
recovery time following an acute jejunal injury in rats induced by intrajejunal SDS exposure for 15 
min in a single-pass intestinal perfusion model [12,22]. Three drugs—teduglutide, misoprostol, and 
melatonin—with different mechanisms of action were administered by different routes alone and in 
combination. Their effects were investigated by monitoring CLCr-EDTA excretion into the jejunum over 
time and by evaluating histology on the same intestinal segment. 
Injury or dysregulation of the epithelial barrier may result in an increased intestinal permeability 
[5–7]. The medical potential is therefore considerable for drug treatment strategies directly targeting 
recovery of the epithelial barriers. Such drug treatments may halt disease progression in patients with 
conditions related to a compromised intestinal barrier as well reduce GI-related side effects following 
chemotherapy. The mechanism of SDS-induced injury is related to its surfactant properties—
monomers are incorporated into the epithelial bilayer, causing destabilization of the membrane and 
the tight junction protein complex [23–25]. This increases the passive intestinal transport of a range 
of compounds in both absorptive and secretory directions and blocks constitutive endocytosis 
[20,26,27]. The effects on intestinal permeability after exposure to SDS are both concentration- and 
time-dependent and accompanied by biochemical and histological features of intestinal injury 
[19,22]. Other common rodent models for studying epithelial injury are the ischemia–reperfusion 
model; the use of knockout mice lacking vital paracellular junction proteins; and chemical agents 
inducing epithelial damage, such as bile salt, trinitrobenzene sulfonic acid, acetic acid, or dextran 
sodium sulfate [28–32]. The similarity to SDS in acute effects on the mucosal barrier in these models 
makes us confident that SDS can be used to investigate the dynamic barrier-protective effect of a 
range of drugs.  
Pretreating rats with a selective COX-2 inhibitor, such as parecoxib, has been shown to restore 
normal intestinal physiology following laparotomy as the surgery itself causes postoperative 
intestinal paralysis, partly mediated by COX-2-derived intestinal prostacyclin [33]. The paralysis 
attenuates intestinal functions, such as motility, alkaline secretion, osmoregulation, and water 
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Alcian blue–PAS (pH 2.5)-stained mucus (original magnification ×400). (A) The villous tip contain
a moderate, densely packed infiltrate of macrophages, lymphocytes, plasma cells, and eosinophils.
No neutrophils were present. (B) An edema is shown with an increase of the intercellular stroma
and a loose presence of inflammatory cells and fibrocytes. Lymphatic and blood vessels are dilated.
The epithelium is intact. (C) A continuous small layer of magenta-positive mucus at the luminal apical
face of the enterocytes. The goblet cells display a blue-purple mucus. Apoptotic cells and macrophages
containing small mucus droplets are seen under the epithelium. Experimental groups: (A) melatonin
100 mM, (B) isoprostol 10 mM, and (C) control.
3. isc ssi
is st i esti ate t e te tial f treati a i j re i testi al arrier, ic is c
i a I and systemic diseases [5]. The main objective was to investigate the protective effects
and recovery time followi g an acute jejunal injury in rats induced by intrajejunal SDS exposure for
15 mi in a single-pass intestinal perfusion model [12,22]. Three drugs—teduglutide, misoprostol,
and melatonin—with different mechanisms of action were administered by different routes alone and
in combination. Their effects were investigated by monitoring LCr-EDTA excretion into the jejunum
over time and by evaluating histology on the same intestinal segment.
I j r or dysregulation of the epithelial barrier may result in an increased intestinal
permeability [5–7]. The medical potential is therefore consider ble for drug treatment strategies
directly targeting recovery of the epithelial barriers. Such drug treatments may halt disease progression
in patients with conditi ns related to a compromised intestinal barrier as well reduc GI-related side
eff cts following che ot erapy. The mechanism of SDS-induced injury is related to its surfactant
pr perties—mo omers are i c rporated into the epithelial bilayer, causing destabilization of the
m mbrane and the tight junction protein complex [23–25]. This increases the passive intestinal
transport of a range of comp unds in both absorptive and secretory directions and blocks constitutive
endocytosis [20,26,27]. Th effects on intestin l permeability after exposure to SDS are both
concentration- and time-de e dent and acco p nied by biochemical and histological features
of intestinal injury [19,22]. Other common rode t models for studying epithelial injury are the
ischemia–reperfusion m del; th use of knockout mice lacking vital aracellular junction prot i s;
and hemical agents inducing epithelial damage, such as bile salt, trinitrobenzene sulfonic acid,
acetic acid, or dextran sodium sulfate [28–32]. The similarity to SDS in acute effects on the mucosal barrier
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in these models makes us confident that SDS can be used to investigate the dynamic barrier-protective
effect of a range of drugs.
Pretreating rats with a selective COX-2 inhibitor, such as parecoxib, has been shown to restore
normal intestinal physiology following laparotomy as the surgery itself causes postoperative intestinal
paralysis, partly mediated by COX-2-derived intestinal prostacyclin [33]. The paralysis attenuates
intestinal functions, such as motility, alkaline secretion, osmoregulation, and water transport, which may
all affect the relevance of the data [34]. Furthermore, parecoxib has been previously shown to have no
effect on basal intestinal permeability in rats [35] and had no effect on SDS-induced epithelial injury
in our present study. Therefore, parecoxib was included in all other study groups to permit optimal
physiological conditions for the SPIP model.
Teduglutide was developed for the treatment of short bowel syndrome. It stimulates intestinal
growth and inhibits cell apoptosis manifested as an increase in tissue weight, villus height, and crypt
depth [36]. In humans, teduglutide (0.03–0.20 mg/kg/day subcutaneously for >8 weeks) reduces the
need for parenteral nutrient support in short bowel syndrome and has shown promising results for
treatment of Crohn’s disease [37,38]. Similar dosing for one week results in protective effects on the
mucosa and less radiation-induced damage of the small intestine in rats and acid-induced tracheal
damage in mice [17,18] Furthermore, jejunal epithelial permeability of 51Cr-EDTA is reduced as early
as 4 h upon postdosing 5 µg of another GLP-2 analogue (h[Gly 2]GLP-2) in mice and an increased
intestinal blood flow from 1 h after administration (0.9 nmol/kg) in rats [39,40]. However, our study
could not verify any short-term protective effects (from 45 min before SDS exposure) on mucosal injury
after teduglutide (100 µg bolus plus 33 µg/h IV infusion) during 120 min. Hence, additional drug
combination experiments, including teduglutide, were not investigated in this acute intestinal injury
model. However, further studies on the mucosal protective effects of GLP-2 analogues are warranted
in which longer treatment periods should be investigated.
Misoprostol is an agonist for the G-protein-coupled prostaglandin E receptors 1–4 [41].
These receptors are involved in the epithelial homeostasis and protect against mucosal damage;
misoprostol is therefore used for the prevention of nonsteroidal anti-inflammatory drug-induced
mucosal erosions and ulcers [16,42]. It does so by regulating gastric acid secretion, mucus secretion,
and proinflammatory cytokine production and by activating adaptive cell survival pathways through
selective gene repression and splicing [15,43]. Misoprostol, being a prostaglandin analogue, also induces
some early signs of inflammation, such as increased mucosal blood flow and edema, as confirmed
with histology in our study [44]. Accordingly, in the rat intestinal instillation model, pretreating the
colon with misoprostol (1 µM) resulted in a 24% reduction in sodium caprate-induced plasma
exposure of a permeability probe, FITC-dextran [45]. In comparison, our study of the rat jejunum
that used misoprostol (10 µM) resulted in a 50% reduction of the SDS-induced increase in luminal
exposure of 51Cr-EDTA. The abundant preclinical and clinical data supporting the cytoprotective
effects of misoprostol makes it a promising drug for further investigation and treatment of an injured
epithelial barrier.
Melatonin has shown positive treatment effects in irritable bowel syndrome and inflammatory
bowel disease [46,47]. It stimulates duodenal bicarbonate secretion and epithelial barrier function in
rats and mitigates ischemia-, chemical-, and radiation-induced intestinal damage in mice [12,14,31,48].
In rats, both long- and short-term oral and intestinal melatonin attenuate ethanol-induced increases in
duodenal permeability by 50% via a nicotinic receptor-mediated pathway [13,49]. This corresponds
well to the 50% reduction in SDS-induced damage observed in our study, suggesting that the type of
mucosal injury by ethanol and SDS is similar. This is in contrast to the acute duodenal injury induced
by 50 mM hydrochloric acid, which is unaffected by melatonin [13]. This shows that different types of
epithelial barrier injury are mediated via different mechanisms. The effect of melatonin may also differ
between intestinal segments, as illustrated by the lack of effect by melatonin in the jejunum compared
to the duodenum [12]. Similar regional intestinal differences may also explain why IV melatonin was
found to be effective at reducing duodenal, but not jejunal, injury in another study [13]. In summary,
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melatonin has a potent effect on mitigating mucosal injury in the jejunum. This result calls for further
in vivo investigation of the mechanism and how it contributes to mucosal health and barrier regulation
in other intestinal injury and disease models.
The cytoprotective effect following separate administration of misoprostol and melatonin reported
by others, and verified by us, encouraged us to evaluate their combined local effect [50]. This resulted in
a complete abolishment of the SDS-induced increase in CLCr-EDTA. A combined treatment acting on the
mucosal epithelium through different mechanisms may help evade acute mucosal damage. It remains
to be investigated if this also holds true for other drug combinations and in other disease-relevant
experimental models.
Previous in vivo histological investigations following small intestinal exposure of SDS at 10 mg/mL
in rats showed villus shortening, erosion, and eruption [19,51]. These reported effects were evident
directly following a 60 min perfusion and 15 min after an oral bolus, with partial or complete recovery
30 min post the oral bolus dosing. Our study showed increased CLCr-EDTA when SDS (5 mg/mL) was
perfused for 15 min, which suggests epithelial injury [52]. However, the histological examinations of
the jejunal segments revealed no acute mucosal changes. Similar trends have been reported by others;
the substantial effects on CLCr-EDTA induced by 30 min luminal exposure to 15% ethanol does not show
any histological changes [13]. Furthermore, there is no recovery in CLCr-EDTA following 60 min luminal
exposure of 5 mg/mL SDS, indicating that higher concentration and longer exposure time result in
more profound, and most likely permanent, mucosal changes [22]. Consequently, the relationship
between the luminal SDS concentration and exposure time to CLCr-EDTA and histological changes is
not obvious. It needs to be investigated if melatonin and misoprostol reduce potential epithelial injury
observed at longer SDS exposure times.
Our present in vivo model of epithelial barrier function will be used to improve understanding
of chemotherapy-induced mucositis [8,53–55]. The rapid proliferation of IECs, together with the
complex immunological role and interactions with the gut microbiota, makes the GI tract particularly
vulnerable to the tissue-damaging effects of chemotherapeutics. The inability to rapidly repair and
restore epithelial barrier function is detrimental to cancer patients as it can result in various pathologies,
including sepsis and multiple organ dysfunction and failure.
In conclusion, our single-pass jejunal perfusion study showed that separate pharmacological
treatments with luminal misoprostol and melatonin reduced acute SDS-induced intestinal injury,
while their use in combination exerted a profound preventive effect by abolishing the injury. These data
support further development of drug combinations for oral treatment of conditions and disorders
related to a dysregulated or compromised mucosal epithelial barrier.
4. Materials and Methods
4.1. Materials
Melatonin, SDS, ethanol, accustain (formalin solution 10% neutral buffered), and Inactin
(thiobutabarbital) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Misoprostol was
purchased from Tocris Bioscience (Bristol, UK). Teduglutide was purchased from BOC Sciences (Shirley,
NY, USA). Sodium phosphate dibasic dihydrate (Na2HPO4·2H2O), potassium dihydrogen phosphate
(KH2PO4), sodium hydroxide (NaOH), and sodium chloride (NaCl) were purchased from Merck KGaA
(Darmstadt, Germany). 51Cr-EDTA was purchased from PerkinElmer Life Sciences (Boston, MA, USA).
Parecoxib (Dynastat) was obtained from Apoteket AB, Uppsala, Sweden.
4.2. Study Formulations
Two isotonic (290 mOsm) phosphate-buffered (pH 6.5, 8 mM) perfusate solutions were prepared:
one as a control and the other with SDS (5 mg/mL). These perfusate solutions were investigated with
and without added melatonin (100 µM) and/or misoprostol (10 µM) and following IV administration of
saline solutions of teduglutide (100 µg + 33 µg/h), melatonin (20 mg/kg), and/or parecoxib (10 mg/kg).
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Ethanol stock solutions of melatonin (15 mg/mL) and misoprostol (3.3 mg/mL) were added to the
perfusate solutions with final ethanol concentrations always below 0.5%. Osmolarity was determined
by freezing-point decrement using a Micro Osmometer (Model 3MO; Advanced Instruments,
Needham Heights, MA, USA).
4.3. Animals, Anesthesia, and Surgery
The surgical procedure and experimental setup of the rat SPIP experiment has been previously
described [20]. The study was approved by the local ethics committee for animal research (no. C64/16)
in Uppsala, Sweden. In short, male Han Wistar rats (strain 273) from Charles River Co. (Germany),
body weight 270–395 g, were used. The animals arrived at the animal lab facility at least one week before
the experiment and were allowed water and food ad libitum during this period. Housing conditions
were 12:12 h light–dark cycle and 21–22 ◦C. On the study day, the rats were anesthetized using an
intraperitoneal injection of a 5% w/v Inactin solution (180 mg/kg). Body temperature was maintained at
37.5± 0.5 ◦C. An arterial catheter connected to a transducer-operated PowerLab system (AD Instruments,
Hastings, UK) recorded systemic arterial blood pressure to validate the general condition of the animals.
Rats with a mean blood pressure below 70 mmHg were excluded from the study. The abdomen was
opened along the midline, and a jejunal (6–15 cm) segment was cannulated, covered with polyethylene
wrap, and placed outside the abdomen [56]. The bile duct was cannulated to avoid pancreaticobiliary
secretion into the duodenum.
4.4. Perfusion Study
After completion of surgery, 51Cr-EDTA was administered IV as a bolus of 75 µCi (0.4 mL),
followed by a continuous IV infusion at a rate of 50 µCi per hour (1 mL/h) throughout the experiments.
During the first 30 min following surgery, each jejunal segment was single-pass perfused with
phosphate-buffered saline (6 mM, pH 6.5, 37 ◦C) to stabilize cardiovascular, respiratory, and intestinal
functions and 51Cr-EDTA levels in the circulation. The length and wet tissue weight of each intestinal
segment was determined after the experiment. The single-pass perfusion rate was at all times
0.2 mL/min (peristaltic pump, Gilson Minipuls 3, Le Bel, France).
Following the 30 min stabilization period, nine different SPIP experiments were performed under
different conditions (Figure 5 and Table 2) with continued monitoring of intestinal mucosal integrity.
In two of the nine SPIP experiments, the control solution was perfused for 120 min, with and without
luminal addition of melatonin (100 µM) 30 min into the perfusion. Melatonin was added to investigate
its effect on the basal integrity of the intestinal mucosa, as melatonin has been reported to reduce the
basal duodenal permeability in male Sprague Dawley rats [12].
Seven of the nine SPIP experiments were divided into three periods. Initially, the segment was
perfused with the control solution for 45 min to establish baseline conditions in each rat. This was
directly followed by a 15 min perfusion of the SDS solution to evaluate the effect on the mucosal
leakage and integrity. Finally, the control solution was perfused for 60 min, after which the recovery of
the mucosa was evaluated.
Initially, the three-part perfusion experiment was performed with and without pretreatment of the
rats with parecoxib (a selective COX-2 inhibitor) to evaluate the basal SDS effect on jejunal permeability.
All other groups were pretreated with parecoxib as it restores physiologic enteric nerve activity after
abdominal surgery [34,35]. Thirty minutes into the 45 min control period (15 min before the start of the
luminal SDS perfusion), either melatonin (100 µM) or misoprostol (10 µM) or melatonin (100 µM) plus
misoprostol (10 µM) were added to the perfusate solutions. The drugs were thereafter present in the
lumen during the remaining 90 min of the three-part perfusion.
In two other experiments, teduglutide (100 µg bolus, followed by infusion 33 µg/h) was
administered IV at t = 0 min and melatonin (20 mg/kg) at t = 30 min. (No further drug combination
experiments with teduglutide were investigated as no effect was observed by administering it
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individually.) The luminal and/or IV administrations of melatonin, misoprostol, and teduglutide were
given to evaluate their effect on SDS-induced mucosal injury.
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The jejunum of rats (n = 6) was single-pass perfused for 120 min with a pH 6.5 saline buffer
it or without ad ing the mucosal irritant SDS at 5 mg/mL between 45 and 60 min. At 30 min
before the start of the SDS experiments, all groups except one (Control SDS without parecoxib) were
intravenously (IV) pretreated with 10 mg/kg parecoxib, a selective cyclooxygenase-2 inhibitor. The three
experimental drugs—melatonin, misoprostol, and teduglutide—were luminally and/or intravenously
administered, individually or in combination, to the rats in order to evaluate their effects on the
SDS-induced mucosal damage. A mesh illustrates that drug is added to the luminal perfusate (buffer
and/or SDS), and stripes illustrates that drug is added intravenously while no change is made to the
luminal perfusate.
Table 2. Conditions and treatments of the nine different experiments. The jejunum of rats (n = 6) was
single-pass perfused for 120 min with a pH 6.5 saline buffer solution (Control) with or without adding
the mucosal irritant SDS at 5 mg/mL between 45 and 60 min. Before the start of the jejunal perfusions,
all groups except one were intravenously (IV) pretreated with 10 mg/kg parecoxib, a selective
cyclooxygenase-2 inhibitor. The three experimental drugs—melatonin (MEL), misoprostol (MIS),
and teduglutide (TED)—were luminally (LUM) and/or intravenously (IV) administered, individually or
in combination, to the rats in order to evaluate their effects on SDS-induced mucosal damage.
Experimental Groups SDS Luminally Addedbetween 45 and 60 min
Drug Treatments
(Dose/Concentration)
Control
No
-
Control MEL-LUM Melatonin lumen (100 µM)
SDS no parecoxib
Yes
-
SDS -
SDS TED-IV Teduglutide IV (100 µg bolus +33 µg/h infusion)
SDS MEL-IV Melatonin IV (20 mg/kg bolus)
SDS MEL-LUM Melatonin lumen (100 µM)
SDS MIS-LUM Misoprostol lumen (10 µM)
SDS MEL-MIS-LUM Melatonin lumen (100 µM) +Misoprostol lumen (10 µM)
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All experimental periods started with a rapid filling (<30 s) of the whole jejunal segment with
the perfusate (about 1.5 mL for a 10 cm segment). The intestinal segment and perfusates were kept
at 37 ◦C, and all outgoing perfusate was collected and weighed at 15 min intervals. Blood samples
(<0.3 mL) were drawn from the femoral artery at the start (t = 0 min) and at the end (t = 120 min) of
the perfusions. The blood samples were centrifuged (5000× g, 3 min at 4 ◦C) within 10 min, and the
plasma was analyzed for 51Cr activity.
For histological examinations, the perfused jejunal segments were excised immediately after the
120 min perfusion, rinsed with tap water, and fixated in formaldehyde. In two separate experiments,
histology was also performed on the intestinal segments directly following the 15 min perfusion of
the SDS solution (i.e., no recovery period) with and without the luminal combination of melatonin
(100 µM) and misoprostol (10 µM).
4.5. Determination of Blood-to-Lumen Jejunal 51Cr-EDTA Clearance
All luminal perfusates and blood plasma were analyzed at 0 and 120 min for 51Cr activity (cpm)
in a gamma counter (1282 Compugamma CS, Pharmacia AB, Sweden). A linear regression analysis
of the plasma samples was made to obtain a corresponding plasma value for each perfusate sample.
The blood-to-lumen CLCr-EDTA was calculated using Equation (1) [57]:
CLCr−EDTA =
Cper f usate × Qin
Cplasma × tissue weight
× 100 (1)
where Cperfusate and Cplasma are the activities in the perfusate and plasma (cpm/mL), respectively, and Qin
is the flow rate (mL/min) in the segment. CLCr-EDTA is expressed as mL/min/100 g wet tissue weight.
CLCr-EDTA values over time from 0 to 120 min are presented from the nine perfusion experiments.
In the evaluation of CLCr-EDTA over time, CLCr-EDTA was normalized against the average value in the
45 min control period. The area under the CLCr-EDTA time curve between 45 and 120 min (CLAUC)
and the maximum CLCr-EDTA concentration (CLmax) were then calculated using noncompartmental
analysis in GraphPad Prism version 7.0 for windows (La Jolla, CA, USA.)
4.6. Histology
Three cross segments of the jejunum—two from regions close to the resection margins and one
from the specimen midpoint—were excised for further investigation. The sections were routinely
prepared and cut into 3 µm slices and stained with hematoxylin and eosin and Alcian blue–PAS
(pH 2.5). An experienced gastrointestinal pathologist assessed the specimen in a blinded fashion using
a light microscope. The following criteria were investigated: epithelial alterations and disruption or
detachment of the epithelium; damage of the mucus layer or altered mucus production; bleeding or
edema; and signs of acute inflammation (as determined by the presence of neutrophils). All tissues
were graded as: (−) no effect, (+) small effect, and (++) clear effect.
4.7. Statistical Analysis
Based on previous studies, a sample size of six rats was used in the CLCr-EDTA experiments
and four in the histology experiments [13,22]. All descriptive CLCr-EDTA statistics are presented as
the mean ± standard deviation (SD) or standard error of the mean (SEM). All values from the nine
groups were compared using a one-way ANOVA with a post-hoc Tukey’s multiple comparison test.
Differences were considered to be statistically significant at p-value < 0.05.
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